Defunct Company
Total Trials
27
As Lead Sponsor
23
As Collaborator
4
Total Enrollment
1,884
NCT00261053
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2003
Completion: Dec 31, 2005
NCT00262288
Phase: Phase 2/3
Start: Apr 30, 2004
Completion: Jan 31, 2007
NCT00262301
Phase: Phase 3
Start: Jun 30, 2004
Completion: Oct 31, 2009
NCT00207337
Exhale (R) Stent for Emphysema
Start: Jul 31, 2004
Completion: May 31, 2006
NCT00225147
Start: Jul 31, 2005
Completion: Jan 31, 2010
NCT00391612
EASE Trial: Exhale Airway Stents for Emphysema
Start: May 31, 2006
Completion: Dec 31, 2013
NCT00851409
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
Start: Jun 30, 2009
Completion: Apr 30, 2010
NCT01067755
Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System
Phase: N/A
Start: Jul 31, 2009
Completion: Mar 31, 2011
NCT01035593
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Start: Dec 31, 2010
Completion: Dec 31, 2011
NCT01188564
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Start: Jan 31, 2011
Completion: Mar 31, 2013
NCT01397864
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Start: Jul 31, 2011
Completion: Dec 10, 2024
NCT01359969
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Start: Jan 17, 2012
Completion: Jul 17, 2017
NCT02247739
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Start: Dec 31, 2014
Completion: Sep 30, 2016
NCT02859727
Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLI
Start: Sep 8, 2016
Completion: Jan 30, 2025
NCT02869347
Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
Role: Collaborator
Start: Jan 31, 2017
Completion: Jul 31, 2018
NCT03697187
Patient Registry to Evaluate the Real-world Safety of Ruconest®
Start: Jun 30, 2018
Completion: Jul 31, 2021
NCT03791476
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
Phase: Phase 1
Start: Jun 21, 2019
Completion: Jan 31, 2022
NCT04414631
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Start: Aug 6, 2020
Completion: Sep 15, 2021
NCT04530136
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Start: Nov 30, 2020
Completion: Dec 1, 2021
NCT04912141
Prevention of Acute Kidney Injury in Patients With NSTEMI
Start: Apr 21, 2021
Completion: Apr 28, 2023
NCT05145283
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
Start: Mar 16, 2022
Completion: Dec 31, 2025
NCT05438407
Pediatric Patients Aged 4 to 11 Years With APDS
Start: Feb 1, 2023
Completion: Dec 30, 2025
NCT06249997
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Start: Aug 3, 2023
Completion: Mar 31, 2025
NCT05693129
Pediatric Patients Aged 1 to 6 Years With APDS
Start: Aug 30, 2023
Completion: Feb 28, 2026
NCT06549114
Leniolisib for Immune Dysregulation in PIDs
Start: Oct 21, 2024
Completion: Oct 31, 2025
NCT06897358
Leniolisib for Immune Dysregulation in CVID
Start: Feb 12, 2025
Completion: Oct 31, 2026
NCT06990529
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Start: Apr 29, 2025
Completion: Apr 13, 2029